Afficher la notice abrégée

Outcomes of targeted treatment in immunocompromised patients with asymptomatic or mild COVID-19: a retrospective study

dc.rights.licenseopenen_US
dc.contributor.authorLAHOUATI, M.
dc.contributor.authorCAZANAVE, C.
dc.contributor.authorLABADIE, A.
dc.contributor.authorGOHIER, P.
dc.contributor.authorGUIRLÉ, L.
dc.contributor.authorDESCLAUX, A.
dc.contributor.authorGIGAN, M.
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorMALVY, Denis
dc.contributor.authorPEDEBOSCQ, S.
dc.contributor.authorXUEREB, F.
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorDUVIGNAUD, Alexandre
dc.date.accessioned2023-12-18T09:58:27Z
dc.date.available2023-12-18T09:58:27Z
dc.date.issued2023-09-16
dc.identifier.issn2045-2322en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/186689
dc.description.abstractEnThe aim of this study was to describe the outcomes of targeted COVID-19 treatments in immunocompromised patients with asymptomatic or mild COVID-19 during the period of expansion of the different Omicron subvariants in France. A retrospective monocentric observational study was performed. All immunocompromised patients aged 18 or more, with asymptomatic SARS-CoV-2 infection or mild COVID-19, and who had received a targeted treatment with sotrovimab, tixagevimab/cilgavimab, nirmatrelvir/ritonavir or remdesivir at the Bordeaux University Hospital from 1st January 2022 to 31st December 2022 were eligible. The primary outcomes of interest was defined as a composite of either (i) progression to moderate (WHO-Clinical Progression Scale at 4 or 5) or severe COVID-19 (WHO-CPS >= 6), or (ii) the occurrence of COVID-19-related death. The secondary outcomes of interest were the components of the primary outcome. Outcomes were collected until day 30 after targeted treatment administration or at discharge for patients still hospitalised in relation with COVID-19 at day 30. 223 immunocompromised patients received targeted treatment for asymptomatic SARS-CoV-2 infection or mild COVID-19: 114 received sotrovimab, 50 tixagevimab/cilgavimab, 49 nirmatrelvir/ritonavir, and 10 remdesivir. Among 223 treated patients, 10 (4.5%) progressed to moderate or severe disease: three patients (1.3%) progressed to moderate COVID-19 and 7 (3.1%) patients progressed to severe disease. Among them, 4 (1.8%) died of COVID-19. More than 95% of immunocompromised patients with asymptomatic SARS-CoV-2 infection or mild COVID-19 treated by targeted therapies during the Omicron subvariants era did not progress to moderate or severe disease.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.title.enOutcomes of targeted treatment in immunocompromised patients with asymptomatic or mild COVID-19: a retrospective study
dc.title.alternativeSci Repen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1038/s41598-023-42727-5en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed37717101en_US
bordeaux.journalScientific Reportsen_US
bordeaux.page15357en_US
bordeaux.volume13en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDInstitut de Recherche pour le Développementen_US
hal.identifierhal-04402876
hal.version1
hal.date.transferred2024-01-18T12:29:37Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Scientific%20Reports&rft.date=2023-09-16&rft.volume=13&rft.issue=1&rft.spage=15357&rft.epage=15357&rft.eissn=2045-2322&rft.issn=2045-2322&rft.au=LAHOUATI,%20M.&CAZANAVE,%20C.&LABADIE,%20A.&GOHIER,%20P.&GUIRL%C3%89,%20L.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_SciRep_2023_Lahouati.pdf
Taille:
942.5Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée